Publications by authors named "A Gonzalez-Cantero"
Article Synopsis
- Psoriasis is linked to higher cardiovascular risk, but how this connection works is not well understood, especially regarding systemic inflammation and skin disease severity.
- The study aims to determine if systemic inflammation acts as a mediator between the severity of psoriasis and cardiovascular disease using data from two patient cohorts in the U.S. and Sweden.
- Key outcomes analyzed include coronary artery health using advanced imaging and rates of hospitalization or death due to cardiovascular issues, with a focus on the roles of psoriasis severity and inflammation markers.
Introduction: Studies directly comparing the effectiveness of different biologics over long observation periods are lacking. As many treatment guidelines are formulated based on drug class, there is a particular need to compare drug classes rather than specific biologic agents.
Methods: This post hoc analysis compares the effectiveness and durability of biologics that target the interleukin (IL)-17 A ligands or the IL-17 receptor A (IL-17RA) relative to other approved drug classes in patients with moderate-to-severe plaque psoriasis, through 12 months in a real-world setting.
Background And Objective: Risankizumab - a humanized monoclonal antibody that targets the p19 subunit of IL-23 - has been recently approved to treat moderate-to-severe plaque psoriasis. Real-world data based on a representative pool of patients are currently lacking.
Objective: To assess the mid- and long-term safety and efficacy profile of risankizumab in patients with moderate-to-severe psoriasis in the routine clinical practice.
Subclinical Atherosclerosis in Alopecia Areata: Usefulness of Arterial Ultrasound for Disease Diagnosis and Analysis of Its Relationship with Cardiometabolic Parameters.
J Clin Med
July 2024
Unlabelled: Chronic systemic inflammation is a risk factor that increases the development of atherosclerosis and predisposes to cardiovascular diseases (CVDs). The systemic inflammatory profile of alopecia areata (AA) regarding IFNγ and Th1 cytokine dysregulation has previously been described, suggesting an increased incidence of CVDs in this population. No previous studies investigated the possible relationship between atherosclerosis and AA by cardiovascular imaging techniques.
View Article and Find Full Text PDFArticle Synopsis
- The National Psoriasis Foundation suggests assessing the effectiveness of plaque psoriasis treatments at 12 weeks, aiming for minimal skin involvement with ixekizumab (IXE) compared to other biologics.
- A study evaluated four randomized clinical trials and a real-world study focused on moderate-to-severe psoriasis patients treated with IXE or various other biologics.
- Results indicated that IXE led to significantly better outcomes in achieving target and acceptable responses at 12 weeks compared to etanercept, guselkumab, and ustekinumab, as well as other approved treatments in real-world scenarios.